Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 39.68 CNY 0.61%
Market Cap: ¥9.1B

EV/IC

1.6
Current
39%
Cheaper
vs 3-y average of 2.7

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.6
=
Enterprise Value
¥6.6B
/
Invested Capital
¥4.1B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.6
=
Enterprise Value
¥6.6B
/
Invested Capital
¥4.1B

Valuation Scenarios

Shanghai Haohai Biological Technology Co Ltd is trading below its 3-year average

If EV/IC returns to its 3-Year Average (2.7), the stock would be worth ¥65.21 (64% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+223%
Average Upside
103%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.6 ¥39.68
0%
3-Year Average 2.7 ¥65.21
+64%
5-Year Average 3.4 ¥82.18
+107%
Industry Average 5.3 ¥128.14
+223%
Country Average 1.9 ¥46.85
+18%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
9B CNY 1.6 35.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -1 260 263.1 -160 127.7
US
Abbvie Inc
NYSE:ABBV
360.5B USD 4.4 86.1
US
Amgen Inc
NASDAQ:AMGN
182.2B USD 3.7 23.6
US
Gilead Sciences Inc
NASDAQ:GILD
159.9B USD 3.6 18.8
US
Epizyme Inc
F:EPE
94.1B EUR 966.7 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.5B USD 7.3 27.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD 5.4 16.1
NL
argenx SE
XBRU:ARGX
40.6B EUR 14.5 36.7
US
Seagen Inc
F:SGT
39.3B EUR 20.8 -61.8
AU
CSL Ltd
ASX:CSL
60.6B AUD 1.5 29.4
P/E Multiple
Earnings Growth PEG
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average P/E: 34.2
35.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.1
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.6
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
14%
1.2
NL
argenx SE
XBRU:ARGX
36.7
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.4
9%
3.3

Market Distribution

In line with most companies in China
Percentile
44th
Based on 7 566 companies
44th percentile
1.6
Low
0 — 1.1
Typical Range
1.1 — 3.4
High
3.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.1
Median 1.9
70th Percentile 3.4
Max 1 129 391.6

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
9.1B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 28%
Intrinsic Value
Price ¥39.68
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett